HSBC Holdings plc reiterated a reduce rating and set a GBX 4,100 ($53.93) price target on shares of AstraZeneca plc in a report on Monday, September 11th.
Shares of AstraZeneca plc (LON:AZN) opened at GBX 4,870 ($64.05) on Wednesday. The company has a consensus rating of Hold and a consensus target price of GBX 5,247.18 ($69.01). The new target price indicates a possible downside of -0.04% based on the company's last stock close price. The brokerage now has a GBX 5,600 ($73.66) target price on the biopharmaceutical company's stock. Berenberg Bank set a GBX 5,550 ($70.51) price objective on shares of AstraZeneca plc and gave the stock a "buy" rating in a research note on Thursday, August 25th. The company has a market cap of $83,831.08, a P/E ratio of 7.90, a P/E/G ratio of 2.77 and a beta of 0.75. AstraZeneca plc has a 1-year low of GBX 3,996 ($52.56) and a 1-year high of GBX 5,520 ($72.60).
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings results on Thursday, November 9th. Astrazeneca PLC's revenue for the quarter was up 9.4% compared to the same quarter a year ago.
TRADEMARK VIOLATION NOTICE: "BMO Capital Markets Reaffirms "Buy" Rating for Astrazeneca PLC (AZN)" was reported by BBNS and is the property of of BBNS. If you are reading this report on another website, it was copied illegally and reposted in violation of United States and worldwide copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/11/12/shore-capital-reaffirms-hold-rating-for-astrazeneca-plc-azn.html.
Etrade Capital Management LLC augmented its stake by buying 30,435 shares an increase of 35.5% in the quarter. The company's stock had a trading volume of 3,189,397 shares, compared to its average volume of 1,940,000. Bronfman E.L. Rothschild L.P. raised its position in Astrazeneca PLC by 71.2% in the second quarter. Westport Asset Management Inc. bought a new stake in Astrazeneca PLC in the second quarter worth about $170,000.
COPYRIGHT VIOLATION WARNING: This report was first reported by Week Herald and is owned by of Week Herald.
AstraZeneca PLC (AstraZeneca), launched on June 17, 1992, is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold.